Dr. Mark Ellison brings over 25 years of pharmaceutical expertise, specializing in advancing start-ups and small pharma through the development process to market. As Chief Development Officer at Opiant Pharmaceuticals, he played a crucial role in developing Narcan Nasal Spray and Opvee (Nalmefene) Nasal Spray, both pivotal in combating opioid overdose. His experience also includes leadership positions at S.L.A. Pharma, the Medicines and Healthcare Products Regulatory Agency (MHRA), and Merck, where he focused on clinical development and regulatory affairs.
President of Clinical Operations and Chief Development Officer